Aurobindo Pharma reported a robust Q1FY27 with net profit up 25.2% to ₹1,032 Cr. Revenue grew 16.3% to ₹9,150 Cr, driven by the U.S. market and new product launches.
Aurobindo Pharma Q1FY27 Results: Profit Soars 25.2% on Robust Revenue Growth
Consolidated Net Profit: ₹1,032 Cr (+25.2% YoY) Consolidated Revenue: ₹9,150 Cr (+16.3% YoY) Reader Takeaway: Strong U.S. growth and biosimilar expansion offset API softness, signaling positive fiscal year start. ## What just happened Aurobindo Pharma announced its Q1FY27 financial results, showcasing a significant 25.2% year-on-year increase in net profit to ₹1,032 crore. Consolidated revenue climbed 16.3% to ₹9,150 crore, while operating EBITDA rose 20.0% to ₹1,924 crore. The company reported an Earnings Per Share (EPS) of ₹17.86. ## Why this matters The strong financial performance indicates healthy growth across Aurobindo Pharma's key business segments. The substantial increase in net profit and revenue signals effective operational execution and market traction, which is positive for shareholders. ## The backstory In Q1FY26, the company had reported a net profit of ₹824 crore and revenue of ₹7,868 crore. This quarter's results demonstrate a sustained upward trend in profitability and sales. ## What changes now The company's strategic initiatives, including new product launches in the U.S. and expansion in biosimilars and biologics, appear to be yielding positive results. Progress on capacity expansion, such as the inauguration of the TheraNym Unit 1, positions the company for future growth. ## Risks to watch Investors should note a one-time expense of ₹43 crore related to lease receivable derecognition, which impacted operating EBITDA. Additionally, API revenues faced sequential performance impacts due to seasonal softness in the antibiotics portfolio. ## Peer comparison While direct Q1FY27 peer data isn't available in this filing, Aurobindo's growth figures suggest competitive performance within the Indian pharmaceutical sector, particularly in its U.S. generics and emerging biosimilars segments. ## Context metrics (time-bound) * U.S. Business contributed 41.2% of consolidated revenue. * 10 new products were launched in the U.S. market during Q1FY27. * CuraTeQ Biologics unit received ANVISA GMP certification. * TheraNym Unit 1 was inaugurated on June 3, 2026. * AuroVaccines merger is targeted for completion by March 2027. ## What to track next Investors will be keen to monitor the continued scaling of the CuraTeQ biologics platform and the successful integration of new manufacturing units. Performance in the API segment and the impact of new product launches will also be crucial indicators.
